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The  plasma  disposition,  faecal  excretion  and  efﬁcacy  of  two  formulations  of pyrantel
pamoate  in  donkeys  were  examined  in  a controlled  trial.  Three  groups  of seven  donkeys
received  either  no  medication  (control)  or pyrantel  paste  or granule  formulations  at
horse  dosage  of  20 mg/kg  B.W.  (equals  6.94 mg/kg  PYR  base)  of body  weight.  Heparinized
blood  and  faecal  samples  were collected  at various  times  between  1 and  144  h  after
treatment.  The  samples  were  analysed  by  high-performance  liquid  chromatography.
The  last  detectable  plasma  concentration  (tmax)  of  paste  formulation  was  signiﬁcantly
earlier  (36.00  h)  compared  with  granule  formulation  (46.29  h).  Although,  there  was  no
signiﬁcant  difference  on  terminal  half lives  (t1/2: 12.39  h  vs. 14.86  h), tmax (14.86  h  vs.
14.00)  and  MRT  (24.80  h  vs.  25.44  h)  values;  the  Cmax (0.09  g/ml)  AUC (2.65  g  h/ml)
values of  paste  formulation  were  signiﬁcantly  lower  and  smaller  compared  with  those  of
granule  formulation  (0.21  g/ml  and  5.60  g h/ml),  respectively.  The  highest  dry  faecal
concentrations  were  710.46  g/g and  537.21  g/g  and  were  determined  at 48 h  for both
paste  and  granule  formulation  of  PYR  in donkeys,  respectively.  Pre-treatment  EPG  of
1104,  1061  and  1139  were observed  for the  control,  PYR  paste  and  PYR  granule  groups,
respectively.  Pre-treatment  EPG  were  not  signiﬁcantly  different  (P > 0.1)  between  groups.
Post-treatment  EPG  for both  PYR  treatment  groups  were  signiﬁcantly  different  (P <  0.001)
from the  control  group  until  day  35.  Following  treatments  the PYR  formulations  were
efﬁcient  (>95%  efﬁcacy)  until  day  28.  In all studied  donkeys,  coprocultures  performed  at
day—3 revealed  the presence  of  Cyathostomes,  S. vulgaris.  Faecal  cultures  performed  on
different  days  from  C-group  conﬁrmed  the  presence  of  the  same  genera.  Coprocultures
from  treated  animals  revealed  the  presence  of  few larvae  of  Cyathostomes.
∗ Corresponding author. Tel.: +90 266 612 14 61;
fax: +90 266 612 14 48.
E-mail addresses: cengizgokbulut@yahoo.com, cgokbulut@gmail.com
(C. Gokbulut).
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1. IntroductionPyrantel (PYR) is an imidazothiazole derivative,
which belongs to the tetrahydropyrimidine group of
anthelmintics. PYR is available as tartrate and pamoate
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syn. embonate) salts. Different salts of PYR have different
harmacokinetic properties and consequently different
oxicities to the host. The pamoate salt is almost insoluble
n water, poorly absorbed from the gastrointestinal tract,
nd most passes unchanged in the faeces (Arundel, 1983).
educed systemic absorption of the pamoate form poten-
ially increases availability in the lumen of the intestine
Bjorn et al., 1996). The tartrate salt of PYR is soluble
n water and absorbed rapidly and extensively from the
ntestine of monogastric animals (Faulkner et al., 1972).
The daily administration of PYR tartrate to horses at a
ontinuous low level was  highly effective against common
quine parasites, including adult large strongyles (Strongy-
us vulgaris, Strongylus edentatus,  and Triodontophorus spp.),
dult small strongyles (Cyathostomum spp., Cylicocyclus
pp., and Cylicostephanus spp.) and adult and fourth-stage
arascaris equorum (Valdez et al., 1995). It was reported
hat the recommended dose level of PYR (13.2 mg/kg, body-
eight) pamoate paste formulation was effective (95–98%)
gainst infections of Anoplocephala perfoliata (FDA, 2005).
oreover, a recent investigation by Reinemeyer et al., 2010
ndicated that PYR pamoate paste formulation was  highly
ffective against adult (91.2%) and fourth-stage Oxyrus equi
arvae (>99%).
Only limited data are available on the pharmacokine-
ics and efﬁcacy of anthelmintic drugs used in donkeys
ecause donkeys are often a neglected species for studies in
omestic animals. Most of drugs in different classes used in
orses and ruminants are commonly extrapolated for use
n donkeys without optimization of dosing regimens and
etermination of pharmacokinetic properties (Veneziano
t al., 2011). Because of the lack of drugs approved for
se in donkeys, anthelmintics licensed for use in horses
r ruminants are used at the same dosages for treatment
f parasitic infections in donkeys. It has been reported
hat donkeys have a greater capacity to metabolize certain
rugs, compared with the capacity for horses; thus, higher
osages or shorter intervals could be required to maintain
ffective drug concentrations in donkeys (Welfare et al.,
996; Matthews et al., 1997; Coakley et al., 1999; Peck
t al., 2002; Lizarraga et al., 2004; Grosenbaugh et al., 2011).
ence, in the present study, the pharmacokinetic dispo-
ition, faecal excretion and anthelmintic efﬁcacy of two
ifferent formulations (paste and granule) of PYR pamoate
re reported in donkeys naturally infected with intestinal
trongylidae after oral administration.
. Materials and methods
.1. Study Animals
Twenty-one female crossbreed donkeys (Equus asinus)
eighing 200–280 kg were used in this study. The body-
eight (BW) of each animal was estimated 1 day prior to
reatment (day—1) using the nomogram proposed by The
onkey Sanctuary (2003). The animals had a mean age of
.8 (±1.5) years and they had a history of grazing pas-
ure contaminated with equine nematode parasites and
ave not been treated with any anthelmintics during the
revious 9 months. Faecal examinations (individual Faecal
gg Counts and pooled coproculture) performed before thetology 205 (2014) 186–192 187
beginning of the study (day—3) showed individual counts
>150 eggs per gram (EPG) and a high prevalence of intesti-
nal nematodes (Cyathostomes, S. vulgaris) in all studied
donkeys. The study animals were tagged for identiﬁcation
and housed communally in an indoor pen until the day 0 of
the trial. The animals were kept indoors and fed hay-based
diet. Water was provided ad libitum throughout the course
of the study. This investigation was  approved by the Animal
Ethic Committee of University of Naples Federico II.
2.2. Experimental groups
On day—3, 21 of the experimental donkeys had an aver-
age of 1101 ± 583 EPG. The animals were ranked from
lowest to highest EPG counts. Based on increasing EPG
counts, replicates of 3 animals were formed. Within each
replicate, animals were randomly assigned to treatment.
The 21 selected donkeys were assigned consecutively to the
following treatment groups of 7 animals each: PYR paste
treated group (PYR-P group), PYR granule treated group
(PYR-G-group), and untreated control group (C-group).
2.3. Drug administration
Commercially available equine formulations of PYR
paste (Strike PYR paste pamoate 38%, Acme, Italy) and PYR
pamoate granulate (Strike, PYR pamoate 20%, Acme, Italy)
licensed for horses were administered orally to donkeys at
a recommended dosage rate of 20 mg/kg B.W. which equals
6.94 mg/kg PYR base.
2.4. Sampling procedure
Heparinized blood samples were collected by jugular
venipuncture prior to drug administration and 1, 2, 4, 8,
12, 16, 24, 30, 36, 48, 56, 72, 96, 120 and 144 h thereafter.
Faecal samples (>10 g) were collected per rectum through-
out the blood-sampling period, before drug administration
and then at 4, 8, 12, 16, 24, 30, 36, 48, 56, 72, 96 and 120 h
in order to determine faecal excretion of PYR under study.
Blood samples were centrifuged at 1825 × g for 30 min and
plasma was transferred to plastic tubes. All the plasma and
faecal samples were stored at −20 ◦C until estimation of
drug concentration.
2.5. Analytical procedure
The parent compound of PYR was analysed by high per-
formance liquid chromatography (HPLC). The liquid–liquid
phase extraction procedure used for PYR was adapted from
that described by McKellar et al. (1993a). Brieﬂy, 1 ml  drug-
free plasma samples were fortiﬁed with PYR standard to
reach the following ﬁnal concentrations: 0.01, 0.05, 0.1,
0.5, 1 and 5 g/ml. Morantel citrate was  used as an inter-
nal standard. Sodium hydroxide (NaOH) (0.5 ml,  0.4 M)  was
added to tubes. After vortex for 15 s, 6 ml  chloroform was
added. The tubes were shaken for 2 min. After centrifuga-
tion at 2000 × g for 15 min, 4 ml  of the organic phase was
transferred to the glass tube and evaporated to dryness at
43 (C in a sample concentrator—Maxi-dry plus, Heto Lab.
Equipment, Denmark). The dry residue was dissolved in
y Parasi
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300 l of the mobile phase and 100 l of this solution was
injected into the chromatography system.
Faecal material was mixed with a spatula to obtain
a homogeneous sample. Drug-free faecal samples (0.5 g)
were fortiﬁed with PYR standard to reach the following
ﬁnal concentrations: 1, 5, 50, 100, and 300 g/g. Moran-
tel citrate was used as an internal standard. Acetonitrile
(2 ml)  was added to tubes containing 0.5 g fortiﬁed blank
samples and experimental samples. After vortex for 15 s,
6 ml  chloroform was added. The tubes were shaken for
2 min. After centrifugation at 2000 × g for 15 min, 4 ml  of
the organic phase was transferred to a glass tube and evap-
orated to dryness at 43 (C in the sample concentrator. The
dry residue was dissolved in 300 l or 5 ml  of the mobile
phase and 50 l of this solution was injected into the chro-
matography system. Because of the photosensitivity of PYR
all preparative processes were conducted in covered con-
tainers. To determine the dry weight of wet faecal samples,
1.0 g of wet faeces from each sample was weighed exactly
into an evaporating bowl and heated in an oven at 70 ◦C for
10 h. The weight of each sample was determined and the
percentage of each dry sample was calculated.
In the HPLC system, a mobile phase of acetonitrile:water
(30:70) with 0.6% (v/v) triﬂouro acetic acid (TFA) pumped
(1100 Series QuatPump, Agilent, Waldron, Germany) at
ﬂow rate 1 ml/min was used for plasma samples and ace-
tonitrile:water (15:85) with 0.6% (v/v) TFA pumped at
ﬂow rate 1.4 ml/min was used for faecal samples. A nucle-
osil C18 analytical column (Luna, 4 m,  150 mm × 4.6 mm,
Phenomenex, Macclesﬁeld, Cheshire, UK) with nucleosil
C18 guard column (Phenomenex, Macclesﬁeld, Cheshire,
UK) was used with ultraviolet detection (1100 Series PDA
detector, Agilent, Waldron, Germany) at a wavelength of
322 nm.
The analytical methods used for PYR in plasma and
faecal samples were validated prior to the start of the stud-
ies. The analyte was identiﬁed with the retention times of
pure reference standard. Recoveries of the molecule under
study were measured by comparison of the peak areas of
spiked plasma and faecal samples with the areas resulting
from direct injections of standards prepared in acetonitrile.
The inter- and intra-assay precision of the extraction and
chromatography procedures were evaluated by processing
replicate aliquots of drug-free donkey plasma and faecal
samples containing known amounts of the drugs on differ-
ent days.
Calibration graph for PYR was prepared (linear range
0.01–5 g/ml in plasma and 1–300 g/ml faecal analysis).
The slope of the lines between peak areas and drug concen-
tration was determined by least squares linear regression
and correlation coefﬁcient (r) and coefﬁcient of variations
FECR(%) = M(CV) calculated. Linearity was established to determine
the PYR concentration/detector response relationship. The
detection limit of PYR was established with HPLC analy-
sis of blank plasma fortiﬁed with the standard, measuringtology 205 (2014) 186–192
the baseline noise at the retention time of the peak. The
mean baseline noise at the peak retention time, plus three
standard deviations was  deﬁned as the detection limit
(LOD). The mean baseline noise plus six standard deviations
was  deﬁned as the limit of quantiﬁcation (LOQ).
2.6. Coprological examinations and anthelmintic efﬁcacy
According to general recommendations proposed by
Nielsen et al. (2010) faecal samples were taken from the
rectum from each study animal, were stored in a refrig-
erator (4 ◦C) and individual faecal egg counts (FEC) were
performed, within 12 h before the start of the trial (day—3),
at days 0, 7, 14, 21, 28, 35, 42 and 56 after treatment. Indi-
vidual faecal egg counts were determined using a modiﬁed
McMaster technique with a detection limit of 10 EPG, using
a Sheather’s saturated sugar solution with a speciﬁc gravity
of 1.260 (MAFF, 1986).
On each sampling day, individual faecal samples were
incubated at 27 ◦C for 7–10 days for larval identiﬁcation.
Only before the start of the trial (day–3) were performed
pooled coprocultures. Third stage larvae were identiﬁed
using the morphological keys proposed by MAFF (1986).
When a coproculture had 100 or fewer third stage larvae,
all were identiﬁed; when a coproculture had more than 100
larvae, only 100 were identiﬁed.
To determine the efﬁcacy of PYR against intestinal
strongyles at each faecal sampling time, the arithmetic
mean of EPG was calculated. Following the American Asso-
ciation of Equine Practitioners (AAEP) Parasite Control
Guidelines (Nielsen et al., 2013a), for each animals percent
efﬁcacy (%) was  calculated in terms of faecal Egg Count
Reduction (FECR) at the different days according to the
formula:
G (before treatment) − Mean EPG (after treatment)
Mean EPG (before treatment)
×  100
2.7. Pharmacokinetics and statistical analysis of data
The plasma concentration vs. time curves obtained
after each treatment in individual animals, were ﬁt-
ted with the WinNonlin software program (Version 5.2,
Pharsight Corporation, Mountain View, CA, USA). The phar-
macokinetics parameters for each animal were analysed
using non-compartmental model analysis. The maximum
plasma concentration (Cmax) and time to reach maxi-
mum  concentration (tmax) were obtained from the plotted
concentration-time curve of each drug in each animal. The
trapezoidal rule was  used to calculate the area under the
plasma concentration time curve (AUC):
AUC0→∞ =
n∑Ci + Ci−1 × (ti − ti−1) + Cni=1
2 z
Where C represents the plasma concentration, i-1 and
i are adjacent data point times. The area under the ﬁrst
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Table 1
Mean (±SD) pharmacokinetic parameters of pyrantel (PYR) pamoate paste
and granule following per os administration to donkeys at 20 mg/kg B.W.
(equals 6.94 mg/kg PYR base) bodyweight.
Parameters PYR groups
Paste Granule
t1/2z (h) 12.39 ± 5.35 14.86 ± 5.59
Cmax (g/ml) 0.09 ± 0.02* 0.21 ± 0.07
tmax (h) 14.86 ± 5.52 14.00 ± 9.45
tlast (h) 36.00 ± 0.00* 46.29 ± 4.53
AUClast (g h/ml) 2.65 ± 0.81* 5.60 ± 0.59
AUMClast (g h2/ml) 68.30 ± 36.04* 143.68 ± 64.72
MRTlast (h) 24.80 ± 5.54 25.44 ± 10.68
Cmax: peak plasma concentration; tmax: time to reach peak plasma con-
centration; AUClast: area under the (zero moment) curve from time 0 to
the  last detectable concentration, AUMClast: area under the moment curve
from time 0 to t last detectable concentration; MRTlast: mean residence
time; t1/2z: terminal half-life.
Mean kinetic parameters obtained following PYR paste administration
signiﬁcantly different (* P < 0.01) from those obtained following PYR gran-
ule  administration.
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displayed a similar faecal excretion proﬁles following oral
administration. The highest dry faecal concentrations were
710.46 g/g and 537.21 g/g and were determined at 48 h
Table 2
Mean (±SD) faecal kinetic parameters of pyrantel (PYR) pamoate paste
and granule following per os administration to donkeys at 20 mg/kg B.W.
(equals 6.94 mg/kg PYR base) bodyweight.
Parameters PYR groups
Paste Granule
tmax (h) 46.00 ± 9.73 47.43 ± 5.86
Cmax (g/g) 839.13 ± 212.98 650.39 ± 264.00
tlast (h) 102.86 ± 11.71 109.71 ± 12.83
AUClast (g h2/g) 29,765.56 ± 4687.66 26,414.17 ± 8184.14
MRT (h) 48.43 ± 5.89 53.68 ± 8.18C. Gokbulut et al. / Veterinar
ovement curve (AUMC) was calculated using the equa-
ion:
UMC0→∞ =
n∑
i=1
Citi + Ci−1ti−1
2
×(ti − ti−1)+
(
Cn
2z
+ tnCn
z
)
Thus, the mean residence time (MRT) was calculated as:
RT0→∞ = AUMC0→∞/AUC0→∞
Terminal half-life (t1/2z) was calculated
s:t1/2z = − ln(2)/z
Where z represent the ﬁrst order rate constant associ-
ted with the terminal (log linear) portion of the curve.
The pharmacokinetic parameters are reported as
ean ± SD. Mean pharmacokinetic parameters were statis-
ically compared by one-way analysis of variance (ANOVA).
ll statistical analyses were performed by using MINITAB
or Windows (release 12.1, Minitab Inc., State College, PA,
SA). Mean values were considered signiﬁcantly different
t P < 0.05.
For comparison of the anthelmintic efﬁcacy of both for-
ulations, statistical analysis of data was performed on
rithmetic mean (AM) EPG counts using the parametric t-
est to compare differences between treatment groups for
igniﬁcance at the P < 0.01 level.
. Results
The analytical procedures and HPLC analysis of PYR
ere validated for plasma and faecal analysis. The linear
anges were 0.01–5 g/ml for plasma and 1–300 g/ml fae-
al analysis and showed correlation coefﬁcients of 0.999
nd 0.998, respectively. The mean recovery of PYR from
lasma and faecal samples were 72.72% and 83.56%, respec-
ively. The detection limit of the analytical technique was
.002 g/ml and 0.25 g/ml; the quantiﬁcation limit was
.01 g/ml and 1.00 g/ml for plasma and faecal samples,
espectively. The inter and intra-assay precisions of the
nalytical procedure obtained after HPLC analysis of spiked
tandards of PYR (0.01–5 g/ml) showed a CV of 4.22% and
.54% for plasma and 6.12% and 7.55% for faecal samples,
espectively.
Mean pharmacokinetic parameters of PYR, adminis-
ered orally as paste and granule, are shown in Table 1,
ith the plasma concentration vs. time curves in Fig. 1.
YR was detected in plasma samples between 2 h and 36 h
fter paste administration and 1 h and 48 h after granule
dministration. The last detectable plasma concentration
f paste formulation was signiﬁcantly earlier (36.00 h)
ompared with granule formulation (46.29 h). Although,
here was no signiﬁcant difference on terminal half lives
t1/2: 12.39 h vs. 14.86 h), tmax (14.86 h vs. 14.00 h) and
RT  (24.80 h vs.  25.44 h) values; the Cmax (0.09 g/ml vs.
.21 g/ml) and AUC values (2.65 g h/ml vs. 5.60 g h/ml)
ere signiﬁcantly different in donkeys received paste for-
ulation compared with the animals received granuleormulation, respectively. Mean kinetic parameters of dry-
aeces concentrations after paste and granule formulations
re shown in Table 2 with the dry-faecal concentra-
ion vs. time curves (Fig. 2). PYR was detected in faecalFig. 1. Mean (±SD) plasma concentration (g/g) of pyrantel (PYR)
pamoate paste and granule following oral administration to donkeys at
a  dose rate of 20 mg/kg B.W. (equals 6.94 mg/kg PYR base) bodyweight.
samples between 16 h and 120 h. Both PYR formulationslast
Cmax: peak faecal concentration; tmax: time to reach peak faecal concen-
tration; AUClast: area under the (zero moment) curve from time 0 to the
last detectable concentration; tlast: time to last detectable faecal concen-
tration; MRTlast: mean residence time;
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 GranuleFig. 2. Mean (±SD) dry-faecal concentration (g/g) of pyrantel (PYR)
pamoate paste and granule following oral administration to donkeys at
a  dose rate of 20 mg/kg B.W. (equals 6.94 mg/kg PYR base) bodyweight.
for both paste and granule formulation of PYR in donkeys,
respectively.
Clinically, no adverse reaction was observed in any
of the donkeys treated with PYR during the study. Pre-
treatment EPG of 1104, 1061 and 1139 were observed for
the control, PYR paste and PYR granule groups, respec-
tively. At the start of the study the pretreatment EPG were
not signiﬁcantly different (P > 0.1) between groups. Total
EPG counts and efﬁcacy values for both treated groups com-
pared with the control untreated group (C-group) at each
time study points are shown in Table 3. The results of the
post-treatment EPG for both PYR treatment groups were
signiﬁcantly different (P < 0.001) from the control group
until day 35 following treatments. The PYR formulations
were efﬁcient (>95% efﬁcacy) on days 7, 14, 21 until day 28.
There was no signiﬁcant difference in anthelmintic efﬁcacy
between the two PYR formulations.
In all studied donkeys, coprocultures performed at
day—3 revealed the presence of Cyathostomes and S. vul-
garis. Faecal cultures performed on different days from
C-group conﬁrmed the presence of the same genera. Copro-
cultures from treated animals revealed the presence of few
larvae of Cyathostomes in both PYR groups.
4. Discussion
Although, PYR has been used as an anthelmintic drug
for almost a half century, there is a paucity of data
available in the literature on the pharmacokinetics and
comparative efﬁcacy of different formulations in domestic
animals including equid species. Therapeutic equivalence
was demonstrated for PYR pamoate oral formulations
paste and granule based on FECR test. In this study,
both PYR formulations were highly effective against the
intestinal strongylidae of donkeys until day 28 post treat-
ment. The cutoff values (mean percent reduction in FEC)
for interpreting results of strongyle FECRT suggested
in the guidelines of the AAEP for pyrantel, reported a
range of 94–99% effectiveness expected in the absence
of resistance in horses. The cyathostomin and strongylid
nematodes present in the studied donkeys were apparentlytology 205 (2014) 186–192
susceptible to pyrantel pamoate, as conﬁrmed by FECR val-
ues. The percentage reductions in faecal egg counts for the
PYR paste group, compared to the C-group, were 98.3% on
day 7; 98.5% on day 14; 98.2% on day 21 and 96.6% on day
28.
The percentage reductions in faecal egg counts for the
PYR granule group, compared to the C-group, were 97.1%
on day 7; 97.3% on day 14; 96.3% on day 21 and 96.4% on day
28. The values of efﬁcacy in the present study performed on
the donkey are close to those suggested (92%) by Nielsen
et al., 2013b to evaluate the expected efﬁcacy of pyrantel
against strongyle parasites in horses. The Egg Reappear-
ance Period (ERP) of PYR in the horses is not expected to
exceed 4 weeks (Reinemeyer and Nielsen, 2013); the ERPs
of PYR pamoate paste and granule formulations follow-
ing per os administration in donkeys are fairly similar to
that noted in horses with PYR-susceptible populations of
nematodes and treated at similar dosages.
The results obtained in both treated groups are con-
sistent with the currently approved label claim for PYR
oral formulations against intestinal strongyle parasites of
horses. The mode of administration of PYR would not seem
to alter the anthelmintic efﬁcacy in donkeys.
Even though, the pharmaceutical formulation of
anthelmintic drugs may  affect its bioavailability, which
depends on the rate and extent of absorption of the drug
from the gastrointestinal tract into the bloodstream. The
pharmacokinetic results of the present study obtained after
per os administration of the paste formulation differ sub-
stantially from the granule formulation of PYR in donkeys
at the same dose rate. The plasma level of PYR is much
lower following administration of paste formulation than
those observed following granule administration. After
oral administration, Cmax (0.09 g/ml) was signiﬁcantly
lower (P < 0.01) and AUC (2.65 g h/kg) smaller (P < 0.01)
for PYR paste than PYR granule (Cmax: 0.21 g/ml, AUC:
5.60 g h/kg) given at same dose rates (6.94 mg/kg B.W.).
It is likely that the poorer dissolution of paste formulation
reduces its absorption compared with granule formulation
in donkeys.
The results of PYR in the present study differ substan-
tially from those previously reported by Gokbulut et al.
(2001) in horses at same formulation and administration
route. In the previous study, PYR paste was  administered at
13.3 mg/kg in horses, whereas in this study, it was admin-
istered at 6.94 mg/kg in donkeys. The lower concentrations
and shorter MRT  of PYR in the plasma of horses reﬂect
lower bioavailability and shorter persistence compared
with donkeys. After correction for dose assuming pro-
portionality, Cmax (0.045 g/ml), AUC (0.53 g h/ml) and
MRT  (11.99 h) values in horses much lower than those
observed in the present study (Cmax: 0.09 g/ml, AUC:
2.65 g h/ml and MRT: 24.80 h). The gastrointestinal pas-
sage rate of digesta is affected by alteration in the quality
and quantity of the feed consumed and this could con-
fer variable absorption time and therefore bioavailability
of drugs administered orally. It was  indicated that vari-
ations in the quality (McKellar et al., 1993b; Knox and
Steel, 1997; Oukessou and Souhaili, 1998; Gokbulut et al.,
2007) and quantity (Ali and Hennessy, 1995; Lifschitz et al.,
1997; McKellar et al., 2002; Gokbulut et al., 2010) of diet
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Table  3
Strongyle egg counts in eggs per gram (EPG) and percentage reductions in faecal egg counts (FECR) for donkeys treated with pyrantel pamoate paste (PYR
P-group) and for donkeys treated with pyrantel pamoate granule (PYR G-group), compared with control untreated group (C-group) at each time study
points.
Day C group PYR Paste group FECR (%) P value PYR Granule group FECR (%) P value
EPG AM EPG Range EPG AM EPG Range EPG AM EPG Range
3 1104 450–1470 1061 160–1770 – 0.8636 1139 170–2440 – 0.9220
7  849 450–1170 14 0–30 98.3 0.0000 24 0–80 97.1 0.0000
14  936 500–1340 14 0–30 98.5 0.0000 26 0–10 97.3 0.0000
21  1036 140–1450 19 0–30 98.2 0.0001 39 0–110 96.3 0.0001
28  1334 170–2030 46 0–110 96.6 0.0002 49 20–80 96.4 0.0002
35  1163 610–2000 213 20–740 81.7 0.0003 124 40–290 89.3 0.0001
42  854 90–1370 520 40–1790 39.1 0.2657 303 70–540 64.5 0.0095
 
.2 
* ent P < 0
c
e
a
S
f
d
w
2
t
a
w
a
b
b
(
u
p
a
t
h
u
c
t
a
e
p
5
a
t
t
t
n
h
i
d
p
f
o
p49  823 90–1680 616 10–1950 25.2
56  663 210–1130 737 80–1410 −11
Parametric t-test (PYR-groups vs. C-group) values are signiﬁcantly differ
ould affect the bioavailability of anthelmintics in differ-
nt animal species. Differences among the studies may  be
ssociated with diet type in donkeys compared with horses.
ince in the present study, donkeys were kept indoors and
ed hay-based diet. The horses were yarded for the period
uring and immediately (4 h) after drug administration and
ere then returned to a grass paddock (Gokbulut et al.,
001). Grass-based diet probably decreased gut transit
ime of food, thus the rapid passage of food in the gut causes
 decrease in the bioavailability of PYR in horses compared
ith those in donkeys in the present study. Moreover,
natomic features inﬂuence the passage of digesta, and the
ioavailability and pharmacokinetics of anthelmintics may
e affected by different gut transit time in animal species
McKellar and Scott, 1990).
Parasitism could have had an effect since the donkey
sed in this study were naturally infected with intestinal
arasites and such infections may  have modest effects on
bsorption of anthelmintics (McKellar et al., 1991), unfor-
unately the parasitological status of the horses or the
istory of anthelmintic treatment in the previous study was
nknown.
PYR is not known to have any substantial effect on fae-
al invertebrates, however, it is apparent that faeces from
reated donkeys will have high concentrations of PYR for
t least 120 h for both formulations. This period of faecal
xcretion of PYR is considerably longer in donkeys com-
ared to in the horses (48 h) (Gokbulut et al., 2001).
. Conclusion
The present study demonstrates relatively limited
bsorption of PYR pamoate following per os administra-
ion as paste or granule formulations in donkeys. Although
he higher level and longer persistence of PYR in the gas-
rointestinal tract where the adult stages of most parasitic
ematodes reside after both formulations may  provide
igher and prolong efﬁcacy, low plasma levels could result
n subtherapeutic plasma concentrations. Moreover, the
onkey differs from the horse and requires species speciﬁc
harmacological and parasitological studies. Therefore,
urther research should be carried out to determine the
ptimal dosage and dose scheme for antiparasitic com-
ounds in donkeys.0.5055 533 150–1090 35.2 0.1925
0.7371 651 240–1410 1.7 0.9536
.001—arithmetic means (AM).
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